Astellas reports Phase III data of fezolinetant for menopause-linked VMS

Astellas Pharma has reported topline findings from the Phase III MOONLIGHT 3 clinical trial of fezolinetant to treat moderate to severe vasomotor symptoms (VMS) linked to menopause in women in mainland China.